Corner Therapeutics develops novel immunotherapies focused on generating long-lasting immunity. The company utilizes its proprietary DCITE Platform to enhance dendritic cell activation and function. This approach aims to induce durable immune responses against challenging diseases.
Funding
$54M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer and infectious disease treatments often fail to provide long-lasting immunity, leaving patients vulnerable to recurrence or reinfection. Traditional vaccine and immunotherapy approaches may not effectively stimulate memory T cells, which are crucial for durable protection. This limitation hinders the development of truly preventative and curative therapies.
Solution
The startup offers biotechnology research services leveraging a dendritic cell hyperactivation (hDC) platform to elicit robust and persistent memory T-cell responses. This proprietary technology enhances the ability of dendritic cells to activate and expand antigen-specific T cells, leading to the establishment of long-term immunological memory. By stimulating memory T cells, the hDC platform aims to provide durable protection against a wide range of cancers and infectious diseases. The platform's unique approach focuses on generating a strong and sustained T-cell response, offering the potential for lifelong immunity.
Target Audience
The primary target audience includes biotechnology companies and research institutions focused on developing novel vaccines and immunotherapies for cancer and infectious diseases.
Features
- Dendritic cell hyperactivation (hDC) platform for enhanced T-cell stimulation
- Proprietary methods for generating robust and persistent memory T-cell responses
- Ability to target a wide range of cancers and infectious diseases
- Focus on establishing long-term immunological memory